UBS Group
BLFS icon

UBS Group’s BioLife Solutions BLFS Stock Holding History

UBS Group’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-29,500
Closed -$1.06M – 9390
2021
Q1 		$1.06M Hold
29,500
– – ﹤0.01% 4181
2020
Q4 		$1.18M Buy
+29,500
New +$1.01M ﹤0.01% 3881

Other funds holding BLFS

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

UBS Group's BLFS Position: Q1 2026 in Review

UBS Group increased its BioLife Solutions (BLFS) stake by 9.3% in Q1 2026, buying an estimated $501K and bringing the position to 265,978 shares worth $5.07M. The position accounts for ﹤0.01% of the portfolio, ranked #4071.

UBS Group first reported a position in BLFS in Q4 2014 and has held it in 39 quarters since. The position peaked at $8.64M in Q4 2024. 187 funds tracked by Wall St. Rank hold BLFS as of Q1 2026.

  • UBS Group held 265,978 shares of BioLife Solutions worth $5.07M as of Q1 2026.
  • UBS Group bought 22,673 BioLife Solutions shares in Q1 2026, an estimated $501K.
  • BioLife Solutions made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4071 holding.
  • UBS Group first reported a position in BioLife Solutions in Q4 2014 and has held it in 39 quarters since.
  • UBS Group's BioLife Solutions position peaked at $8.64M in Q4 2024.
  • 187 funds tracked by Wall St. Rank held BioLife Solutions as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.